loading page

British Rhinological Society Consensus Guidance on the use of biological therapies for Chronic Rhinosinusitis with Nasal Polyps
  • +13
  • Claire Hopkins,
  • Jo-Lyn McKenzie,
  • Shahram Anari,
  • Sean Carrie,
  • Yujay Ramakrishnan,
  • Naveed Kara,
  • Carl Philpott,
  • Jonathan Hobson,
  • Ali Qureishi,
  • Benjamin Stew,
  • Philip Harries,
  • Simon Gane,
  • Raj Bhalla,
  • Abigail Walker,
  • Iain Hathorn,
  • Valerie Lund
Claire Hopkins
Guy's and St Thomas' Hospitals NHS Trust

Corresponding Author:[email protected]

Author Profile
Jo-Lyn McKenzie
Royal Brisbane and Women's Hospital
Author Profile
Shahram Anari
University Hospitals Birmingham NHS Foundation Trust
Author Profile
Sean Carrie
Freeman Hospital
Author Profile
Yujay Ramakrishnan
Nottingham University Hospitals NHS Trust
Author Profile
Naveed Kara
County Durham & Darlington NHS Foundation Trust
Author Profile
Carl Philpott
University of East Anglia
Author Profile
Jonathan Hobson
Manchester University NHS Foundation Trust
Author Profile
Ali Qureishi
Oxford University Hospitals NHS Foundation Trust
Author Profile
Benjamin Stew
University Hospital of Wales Healthcare NHS Trust
Author Profile
Philip Harries
University Hospital Southampton NHS Foundation Trust
Author Profile
Simon Gane
Royal National Ear, Nose and Throat and Eastman Dental Hospital
Author Profile
Raj Bhalla
Central Manchester & Manchester Children's Foundation Trust
Author Profile
Abigail Walker
St Georges’ Hospital
Author Profile
Iain Hathorn
University of Edinburgh Division of Medical and Radiological Sciences
Author Profile
Valerie Lund
Royal National Throat Nose and Ear Hospital
Author Profile


Objectives We set out to create Consensus Guidelines, based on current evidence and relative risks of adverse effects and the costs of different treatments, that reflect the views of the British Rhinological Society (BRS) Council on where the use of biologics should be positioned within treatment pathways for CRSwNP, specifically in the setting of the National Health Service (NHS). Methods An expert panel of 16 members was assembled. A review of the literature and evidence synthesis was undertaken and circulated to the panel We used the RAND/UCLA methodology with a multi-step process to make recommendations on the use of biologics. Setting and participants N/A Results Recommendations were made, based on underlying disease severity, prior treatments and co-morbidities. A group of patients for whom biologics were considered an appropriate treatment option for CRSwNP was defined. Conclusions Although biologics are not currently available for the treatment of CRSwNP, the BRS Council have defined a group of patients who have higher rates of ‘failure’ with current treatment pathways, higher resource use and are more likely to suffer with uncontrolled symptoms. We would urge NICE to consider approval of biologics for such indications without applying further restrictions on use.
20 Feb 2021Submitted to Clinical Otolaryngology
27 Feb 2021Submission Checks Completed
27 Feb 2021Assigned to Editor
28 Feb 2021Reviewer(s) Assigned
10 Mar 2021Review(s) Completed, Editorial Evaluation Pending
11 Mar 2021Editorial Decision: Revise Minor
14 Mar 20211st Revision Received
15 Mar 2021Submission Checks Completed
15 Mar 2021Assigned to Editor
21 Mar 2021Reviewer(s) Assigned
27 Mar 2021Review(s) Completed, Editorial Evaluation Pending
28 Mar 2021Editorial Decision: Accept